guest ::
| Home > Publications database > Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. > print |
| Home > Publications database > Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. > print |
| 001 | 136792 | ||
| 005 | 20240229105059.0 | ||
| 024 | 7 | _ | |a 10.1007/s00204-018-2214-z |2 doi |
| 024 | 7 | _ | |a pmid:29761207 |2 pmid |
| 024 | 7 | _ | |a 0003-9446 |2 ISSN |
| 024 | 7 | _ | |a 0340-5761 |2 ISSN |
| 024 | 7 | _ | |a 1432-0738 |2 ISSN |
| 024 | 7 | _ | |a altmetric:41629640 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-01230 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Rodrigues, Robim M |b 0 |
| 245 | _ | _ | |a Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. |
| 260 | _ | _ | |a Berlin |c 2018 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1536239662_3656 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Bosentan is well known to induce cholestatic liver toxicity in humans. The present study was set up to characterize the hepatotoxic effects of this drug at the transcriptomic, proteomic, and metabolomic levels. For this purpose, human hepatoma-derived HepaRG cells were exposed to a number of concentrations of bosentan during different periods of time. Bosentan was found to functionally and transcriptionally suppress the bile salt export pump as well as to alter bile acid levels. Pathway analysis of both transcriptomics and proteomics data identified cholestasis as a major toxicological event. Transcriptomics results further showed several gene changes related to the activation of the nuclear farnesoid X receptor. Induction of oxidative stress and inflammation were also observed. Metabolomics analysis indicated changes in the abundance of specific endogenous metabolites related to mitochondrial impairment. The outcome of this study may assist in the further optimization of adverse outcome pathway constructs that mechanistically describe the processes involved in cholestatic liver injury. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Kollipara, Laxmikanth |b 1 |
| 700 | 1 | _ | |a Chaudhari, Umesh |b 2 |
| 700 | 1 | _ | |a Sachinidis, Agapios |b 3 |
| 700 | 1 | _ | |a Zahedi, René P |b 4 |
| 700 | 1 | _ | |a Sickmann, Albert |b 5 |
| 700 | 1 | _ | |a Kopp-Schneider, Annette |0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |b 6 |u dkfz |
| 700 | 1 | _ | |a Jiang, Xiaoqi |0 P:(DE-He78)079436c5442874052d541943e53145ef |b 7 |u dkfz |
| 700 | 1 | _ | |a Keun, Hector |b 8 |
| 700 | 1 | _ | |a Hengstler, Jan |b 9 |
| 700 | 1 | _ | |a Oorts, Marlies |b 10 |
| 700 | 1 | _ | |a Annaert, Pieter |b 11 |
| 700 | 1 | _ | |a Hoeben, Eef |b 12 |
| 700 | 1 | _ | |a Gijbels, Eva |b 13 |
| 700 | 1 | _ | |a De Kock, Joery |b 14 |
| 700 | 1 | _ | |a Vanhaecke, Tamara |b 15 |
| 700 | 1 | _ | |a Rogiers, Vera |b 16 |
| 700 | 1 | _ | |a Vinken, Mathieu |b 17 |
| 773 | _ | _ | |a 10.1007/s00204-018-2214-z |g Vol. 92, no. 6, p. 1939 - 1952 |0 PERI:(DE-600)1458459-1 |n 6 |p 1939 - 1952 |t Archives of toxicology |v 92 |y 2018 |x 1432-0738 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:136792 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)079436c5442874052d541943e53145ef |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ARCH TOXICOL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ARCH TOXICOL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|